Published in Blood Weekly, September 8th, 1997
Chiron Diagnostics' ACS:180 BR is intended for use as an aid in the management of breast cancer patients with metastatic disease. The test allows clinicians to monitor the cancer's progression or regression in response to treatment. ACS:180 BR is an in vitro diagnostic test for the quantitative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.